Research & Development
We’re committed to developing life-saving diagnostic technologies which address global healthcare needs. Our research and development efforts focus on achieving laboratory-equivalent sensitivity and specificity using point-of-care platforms, delivering rapid, accurate clinical results that patients and healthcare providers can rely on when making treatment decisions.
Our core competencies include:
- Antibody design & development: Detection of analytes in clinical samples is crucial for the early diagnosis of disease. Antibodies can be generated against almost any analyte and the high specificity of antibody-antigen interactions can be exploited for point-of-care diagnostic platform development.
- Bioconjugation: This burgeoning field of research seeks to develop novel methods to bind molecules together. For point-of-care diagnostics, the rapid detection of analytes in clinical samples depends on the development of reusable biosensors which typically consist of biomolecules attached to surfaces via robust bioconjugation linkages.
Advances in technology create opportunities to detect results in point-of-care settings with enhanced sensitivity and selectivity formerly only achievable by central lab equipment.
- Lateral flow Immunoassays (LFIA): Immunoassays are tests that take advantage of the specific binding of an antibody to its antigen. Lateral flow tests are a popular point-of-care platform in which the test sample flows along a solid substrate via capillary action. The sample encounters and mixes with a colored reagent as it passes through the substrate, and the colored reagent can become bound to a test line or zone pretreated with an antibody or antigen based on the analytes present. LFIAs, in their current form, are not easily quantifiable and have sensitivity limitations, and we are developing next generation LFIAs which address those issues.
- Testing Automation: BioMedomics has extensive experience with testing automation, automated staining, and automated imaging systems. We are also developing Artificial Intelligence (A.I.) platforms that enhance results interpretation.
Developing rapid, affordable, accurate, and easy-to-use tests for under-diagnosed diseases of global concern is our primary objective. We are expanding Hematology product offerings and developing point-of-care products for Infectious Disease, and Women’s Health. Oncology is another priority, and our patented nanoparticle-based platform offers the potential for earlier and more precise clinical diagnosis for some cancers and has application for post-treatment monitoring to detect disease recurrence.
The novel technologies in development at BioMedomics will expand business opportunities to diagnose diseases with simple, fast, accurate point-of-care platforms.
These platforms hold promise for a broad range of applications, both clinical and non-clinical, from bio-defense, drug delivery and development, to veterinary diagnostics, substance abuse testing, food safety tests, and environmental monitoring.
Start a Conversation
At BioMedomics, we can’t stop thinking about the possibilities our technologies create. Let’s explore the opportunities together. Send us your thoughts, ideas, and questions, and we’ll connect you with the appropriate staff to continue the conversation.